Avsar.

Healthcare · Pharmaceuticals

Laurus Labs Ltd (LAURUSLABS)

₹1,601.20

Mkt cap
₹86,505 Cr
P/E ratio
79.10
P/B
16.31
Div yield
0.12%
ROE
18.30%
ROCE
17.80%
EPS (TTM)
₹20.24
Book value
₹98
52W range
822–1,608
Sector
Healthcare

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

NSE LAURUSLABSBSE 540222www.lauruslabs.com
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−0.42% from high
₹1,601
₹822+94.83% from low₹1,608
Current
₹1,601.20
Prev close
₹1,608.00
Day
−0.42%
Price performance
1D
−0.42%
1W
+2.71%
1M
+10.43%
3M
+43.81%
6M
+54.63%
1Y
+94.91%
YTD
+44.71%

Financials

F
Revenue, profit & margin
P/E ratio
79.1×
LAURUSLABS is 132% above the sector median of 34.0×
LAURUSLABS79.1×
Sector median34.0×
 Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales1,1821,2241,1951,4401,1951,2241,4151,7201,5701,6531,7781,8122,026
Expenses1,0151,0371,0141,1981,0241,0451,1301,3001,1871,2501,2981,2991,388
Operating Profit167188181241171178285421382403480512638
OPM %14%15%15%17%14%15%20%24%24%24%27%28%32%
Other Income422193595910276129
Interest39425150495358565240394042
Depreciation919398102106108106110117120121122124
Profit before tax4154351071823131312224270327361481
Tax %30%27%27%30%34%22%31%25%28%28%22%22%25%
Net Profit27372375132093233162194252282362
EPS in Rs0.460.690.431.400.230.371.714.333.023.614.665.176.80
Raw PDF

Earnings

EResults dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.13% · closed higher next day 20 of last 42
 Q2FY24Q3FY24Q4FY24Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26†Q3FY26Q4FY26Q1FY27
Broadcast20 Oct '23◦24 Jan '24◦25 Apr '24◦25 Jul '24◦24 Oct '24◦24 Jan '25◦25 Apr '2525 Jul '2523 Jan '2623 Jan '2630 Apr '2624 Jul '26
Earnings day−9.61%−5.51%+2.59%+3.50%+4.14%−11.28%−3.08%+0.15%+1.05%+1.05%−0.47%+2.53%
+1 day−11.05%−6.66%+4.19%+3.95%+10.04%−15.25%−2.94%+6.31%−0.56%−0.56%+5.45%—
+5 days−9.78%−2.07%+3.12%+3.05%+8.98%−1.17%−4.29%+1.54%−5.16%−5.16%+11.05%—
+15 days−7.73%−0.26%+4.40%+0.65%+9.32%−9.37%−5.91%+3.48%+0.66%+0.66%+21.46%—
+30 days−2.72%+2.23%+4.17%+13.16%+28.05%−7.24%+3.38%+7.87%+3.20%+3.20%+25.59%—
FilingXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRLXBRL

Corporate actions

CLast 6 months
KindValueEx-dateRecord
dividend
Interim Dividend - Rs 1.20 Per Share
1.208 May '268 May '26

Results analysis

Shareholding

Sas of Jun 2026
27.47%Promoter
Promoters27.47%0.02
FIIs28.00%2.18
DIIs13.73%0.23
Public30.79%1.94
Ownership trend

Peers

P8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,941.1037.484,65,7350.82%2,710+13.58%14,612+12.76%20.53%
Divi's Lab.₹7,248.5073.361,92,4250.41%751+13.44%2,831+9.52%21.97%
Torrent Pharma.₹4,961.5086.111,88,7200.77%364−20.58%4,197+41.84%15.19%
Cipla₹1,410.6031.841,13,9550.92%786−39.19%7,119+2.33%15.49%
Zydus Lifesci.₹1,108.7020.381,10,5930.09%1,341+21.92%7,587+16.22%21.14%
Lupin₹2,370.5019.061,08,3870.76%1,469+101.49%7,475+31.89%29.93%
Mankind Pharma₹2,507.2051.441,03,5590.04%559+34.23%3,443+11.81%13.53%
Laurus Labs₹1,601.2079.1286,5050.12%362+125.49%2,026+29.10%17.76%
Median: 157 Co.₹432.0534.031,9780.10%15+28.10%176+17.66%15.10%

Filings

D
Annual reports13
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bse
Concall transcripts92
PPTJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025PPTSep 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025PPTApr 2025RECApr 2025TranscriptJan 2025PPTJan 2025RECJan 2025PPTJan 2025TranscriptOct 2024PPTOct 2024RECOct 2024TranscriptJul 2024
Credit ratings6
Rating update 3 JulcareRating update 1 Jul 2025careRating update 20 Jun 2024careRating update 22 Jun 2023careRating update 23 Jun 2022careRating update 23 Mar 2021care
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 21mAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 8h - Laurus Labs reported Q1 FY27 revenue of ₹2,026 crore, EBITDA ₹644 crore, net profit ₹368 crore on July 24, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 8hAnnouncement under Regulation 30 (LODR)-Change in Directorate 8h - Dr. Rajesh Koshy Chandy retires as independent director effective July 26, 2026.Board Meeting Outcome for Outcome Of Board Meeting 8h - Laurus Labs approved Q1 FY27 unaudited results; consolidated revenue rose to ₹2,026.31 crore, profit ₹362.07 crore.